Microbial engineering of new streptomyces sp. from extreme environments for novel antibiotics and anticancer drugs by Asenjo, Juan et al.
MICROBIAL ENGINEERING OF NEW STREPTOMYCES SP. FROM EXTREME ENVIRONMENTS FOR 
NOVEL ANTIBIOTICS AND ANTICANCER DRUGS 
 
J.A. Asenjo, Centre for Biotechnology and Bioengineering, CeBiB, University of Chile 
juasenjo@ing.uchile.cl 
 V. Razmilic, CeBiB, University of Chile 
 J.F. Castro, CeBiB, University of Chile 
 J.P. Gomez, John Innes Centre, Norwich, U.K. 
 A. T. Bull, University of Kent, Canterbury, U.K. 
 M. Goodfellow, Newcastle University, U.K. 
M. Jaspars, University of Aberdeen, U.K. 
 M. Bibb, John Innes Centre, Norwich, U.K.  
B.A. Andrews, CeBiB, University of Chile 
  
 
Keywords : streptomyces, antibiotics, anticancer drugs 
 
Today there is a tremendous need for new antibiotics and novel cytotoxic compounds against cancer cells to 
develop efficient alternative treatment to chemotherapy. We have searched for highly active Streptomyces 
strains in the driest desert in the world, the Atacama desert in northern Chile. We have identified several new 
strains and found many novel antibiotics and anticancer agents (“Chaxamycins”, “Chaxalactins” and 
“Atacamycins”) from Streptomyces C34 and C38. 
 
A genome scale model of the metabolism of Streptomyces leeuwenhoekii C34 has been developed from its 
genome sequence. The model, iVR1007, has 1726 reactions including 239 for transport, reactions for 
secondary metabolite biosynthesis, 1463 metabolites and 1007 genes. The model was validated with 
experimental data of growth in 89, 54 and 23 sole carbon, nitrogen and phosphorous sources, respectively, and 
showed a high level of accuracy (82.5 %). We have included reactions for desferrioxamines, ectoine, 
Chaxamycins, Chaxalactins and for the hybrid polyketides/non-ribosomal peptide synthesized by the 
halogenase cluster. A detailed Metabolic Flux Balance Analysis was carried out in order to study the metabolic 
pathways of Chaxalactins, Chaxamycins and the product of the halogenase cluster, by recognizing 
overexpression targets and useful knock-out sites to increase production of these secondary metabolites. 
 
Alternatively we  have identified the gene cluster in S. leeuwenhoekii C34 responsible for the biosynthesis of the 
Chaxamycins and Chaxalactins and have cloned the whole gene cluster in a much more efficient strain of 
Streptomyces, namely S. coelicolor A3 whose heterologous expression of gene clusters from other 
Streptomyces strains has been successfully tested. Our recent results concerning these two alternative 
strategies for identification and overproduction of these important secondary metabolites will be presented and 
discussed in this presentation. 
 
